(Circulation. 1996;94:690-697.)
© 1996 American Heart Association, Inc.
Articles |
Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction
the Division of Cardiology, University of Texas Medical School, Houston (C.R.B.); the Collaborative Studies Coordinating Center, University of North Carolina, Chapel Hill (B.S.); Victoria General Hospital, Halifax, Nova Scotia, Canada (D.E.J.); the University of Minnesota Hospital, Minneapolis (G.F.); Oregon Health Science University, Portland (B.G.); New England Medical Center, TUFTS, Boston, Mass (M.K.); University of Washington School of Medicine, Seattle (J.L.P.); and McMaster University Medical School, Hamilton, Ontario, Canada (S.Y.).
Background Elevated plasma neurohormonal levels are associated with increased mortality rates in patients with symptomatic heart failure. A previous Studies of Left Ventricular Dysfunction (SOLVD) trial suggested that neurohumoral activation precedes the development of symptoms as demonstrated by increased neurohormonal levels in patients with asymptomatic left ventricular dysfunction. However, the significance of this early neurohumoral activation is unclear. The goals of this study were to determine the prognostic significance of the plasma concentrations of plasma norepinephrine (PNE) and atrial natriuretic peptide (ANP) and the renin activity (PRA) in patients with asymptomatic left ventricular dysfunction.
Methods and Results PNE and PRA were measured before randomization in 514 patients with left ventricular ejection fractions 
35% who did not require treatment for congestive heart failure and were enrolled in the SOLVD Prevention Trial. Plasma ANP levels were measured in a subset of 241 patients owing to study design. Using the Cox proportional hazards model that included left ventricular ejection fraction, New York Heart Association functional class, age, sex, treatment assignment to placebo or enalapril, and cause of heart failure, we examined whether these neurohormones predicted all-cause mortality, cardiovascular mortality, hospitalization for heart failure, development of heart failure, or development of ischemic events (myocardial infarction or unstable angina). PNE was the strongest predictor of clinical events in this patient population. PNE levels above the median of 393 pg/mL were associated with a relative risk of 2.59 (P=.002) for all-cause mortality, 2.55 (P=.003) for cardiovascular mortality, 2.55 (P=.005) for hospitalization for heart failure, 1.88 (P=.002) for development of heart failure, 1.92 (P=.001) for ischemic events, and 2.59 (P=.005) for myocardial infarction. PNE remained the most powerful predictor for all-cause mortality and ischemic events when the analysis included only the patients with histories of ischemic left ventricular dysfunction. The increases in other neurohormonal levels were not useful in predicting the subsequent development of clinical events.
Conclusions Increased PNE levels in patients with asymptomatic left ventricular dysfunction appear to predict all-cause and cardiovascular mortalities and development of clinical events related to the onset of heart failure or acute ischemic syndromes. Thus, measurement of PNE may be a possible early marker for assessment of disease progression in patients with left ventricular dysfunction, and modulating the release or effect of PNE may lead to improved prognosis and/or a reduction in morbidity.
Key Words: norepinephrine • heart failure • atrial natriuretic factor
This article has been cited by other articles:
 |
|
 |
|
  M. Kosiborod, G. E. Soto, P. G. Jones, H. M. Krumholz, W. S. Weintraub, P. Deedwania, and J. A. Spertus Identifying Heart Failure Patients at High Risk for Near-Term Cardiovascular Events With Serial Health Status Assessments Circulation, April 17, 2007; 115(15): 1975 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yang, W.-Z. Zhu, M.-l. Joiner, R. Zhang, C. V. Oddis, Y. Hou, J. Yang, E. E. Price, L. Gleaves, M. Eren, et al. Calmodulin kinase II inhibition protects against myocardial cell apoptosis in vivo Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H3065 - H3075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Anand, F. Razak, A. Davis, R. Jacobs, V. Vuksan, K. Teo, and S. Yusuf Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects Int. J. Epidemiol., October 1, 2006; 35(5): 1239 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Roig Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E12 - E17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Silke Beta-blockade in CHF: pathophysiological considerations Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C13 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Funck-Brentano Beta-blockade in CHF: from contraindication to indication Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C19 - C27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ponikowski Rationale and design of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C35 - C42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Jankowska, P. Ponikowski, M. F. Piepoli, W. Banasiak, S. D. Anker, and P. A. Poole-Wilson Autonomic imbalance and immune activation in chronic heart failure - Pathophysiological links Cardiovasc Res, June 1, 2006; 70(3): 434 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Otte, T. C. Neylan, S. S. Pipkin, W. S. Browner, and M. A. Whooley Depressive Symptoms and 24-Hour Urinary Norepinephrine Excretion Levels in Patients With Coronary Disease: Findings From the Heart and Soul Study Am J Psychiatry, November 1, 2005; 162(11): 2139 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Gold, M.-L. Wong, D. S. Goldstein, H. K. Gold, D. S. Ronsaville, M. Esler, S. Alesci, A. Masood, J. Licinio, T. D. Geracioti Jr., et al. Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia PNAS, June 7, 2005; 102(23): 8303 - 8308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Davis, N. M. Albert, and J. B. Young Palliation of heart failure American Journal of Hospice and Palliative Medicine, May 1, 2005; 22(3): 211 - 222. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Machida, P. M. Heerdt, A. C. Reid, U. Schafer, R. B. Silver, M. J. Broekman, A. J. Marcus, and R. Levi Ectonucleoside Triphosphate Diphosphohydrolase1/CD39, Localized in Neurons of Human and Porcine Heart, Modulates ATP-Induced Norepinephrine Exocytosis J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 570 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J.S. Coats Why ventilatory inefficiency matters in chronic heart failure Eur. Heart J., March 1, 2005; 26(5): 426 - 427. [Full Text] [PDF]
|
|
|
|
|
|
S. Yamamoto, N. Matsumoto, M. Kanazawa, M. Fujita, M. Takaoka, C. E. Gariepy, M. Yanagisawa, and Y. Matsumura Different Contributions of Endothelin-A and Endothelin-B Receptors in Postischemic Cardiac Dysfunction and Norepinephrine Overflow in Rat Hearts Circulation, January 25, 2005; 111(3): 302 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.R. Bristow, H. Krause-Steinrauf, R. Nuzzo, C.-S. Liang, J. Lindenfeld, B.D. Lowes, B. Hattler, W.T. Abraham, L. Olson, S. Krueger, et al. Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the {beta}-Blocker Evaluation of Survival Trial Circulation, September 14, 2004; 110(11): 1437 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Teo, L. B. Mitchell, J. Pogue, J. Bosch, G. Dagenais, S. Yusuf, and on behalf of the HOPE Investigators Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction Circulation, September 14, 2004; 110(11): 1413 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Velez-Roa, A. Ciarka, B. Najem, J.-L. Vachiery, R. Naeije, and P. van de Borne Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension Circulation, September 7, 2004; 110(10): 1308 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schenk, P. M. McCarthy, R. C. Starling, K. J. Hoercher, M. D. Hail, Y. Ootaki, G. S. Francis, K. Doi, J. B. Young, and K. Fukamachi Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 38 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Latini, S. Masson, I. Anand, M. Salio, A. Hester, D. Judd, S. Barlera, A. P Maggioni, G. Tognoni, J. N Cohn, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT Eur. Heart J., February 2, 2004; 25(4): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Clerico and M. Emdin Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review Clin. Chem., January 1, 2004; 50(1): 33 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. El-Armouche, O. Zolk, T. Rau, and T. Eschenhagen Inhibitory G-proteins and their role in desensitization of the adenylyl cyclase pathway in heart failure Cardiovasc Res, December 1, 2003; 60(3): 478 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grassi, G. Seravalle, F. Quarti-Trevano, R. Dell'Oro, G. Bolla, and G. Mancia Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients Hypertension, November 1, 2003; 42(5): 873 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur. Heart J., October 1, 2003; 24(19): 1727 - 1734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sesti, M. Koyama, M. J. Broekman, A. J. Marcus, and R. Levi Ectonucleotidase in Sympathetic Nerve Endings Modulates ATP and Norepinephrine Exocytosis in Myocardial Ischemia J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 238 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Marcus, M. J. Broekman, J. H. F. Drosopoulos, N. Islam, D. J. Pinsky, C. Sesti, and R. Levi Metabolic Control of Excessive Extracellular Nucleotide Accumulation by CD39/Ecto-Nucleotidase-1: Implications for Ischemic Vascular Diseases J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 9 - 16. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. Lanfranchi, V. K. Somers, A. Braghiroli, U. Corra, E. Eleuteri, and P. Giannuzzi Central Sleep Apnea in Left Ventricular Dysfunction: Prevalence and Implications for Arrhythmic Risk Circulation, February 11, 2003; 107(5): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Koyama, N. Seyedi, W.-P. Fung-Leung, T. W. Lovenberg, and R. Levi Norepinephrine Release from the Ischemic Heart Is Greatly Enhanced in Mice Lacking Histamine H3 Receptors Mol. Pharmacol., February 1, 2003; 63(2): 378 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Rousseau, O. Gurne, D. Duprez, W. Van Mieghem, A. Robert, S. Ahn, L. Galanti, J.-M. Ketelslegers, and Belgian RALES Investigators Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy J. Am. Coll. Cardiol., November 6, 2002; 40(9): 1596 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Kitzman, W. C. Little, P. H. Brubaker, R. T. Anderson, W. G. Hundley, C. T. Marburger, B. Brosnihan, T. M. Morgan, and K. P. Stewart Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure JAMA, November 6, 2002; 288(17): 2144 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Johnson, T. Omland, C. Hall, C. Lucas, O. L. Myking, C. Collins, M. Pfeffer, J.-L. Rouleau, and L. W. Stevenson Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1623 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zoccali, F. Mallamaci, S. Parlongo, S. Cutrupi, F. A. Benedetto, G. Tripepi, G. Bonanno, F. Rapisarda, P. Fatuzzo, G. Seminara, et al. Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease Circulation, March 19, 2002; 105(11): 1354 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sesti, M. J. Broekman, J. H. F. Drosopoulos, N. Islam, A. J. Marcus, and R. Levi EctoNucleotidase in Cardiac Sympathetic Nerve Endings Modulates ATP-Mediated Feedback of Norepinephrine Release J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 605 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Nieminen, J. Akkila, G. Hasenfuss, F. X. Kleber, L. A. Lehtonen, V. Mitrovic, O. Nyquist, W. J. Remme, and on behalf of the Study Group Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1903 - 1912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Kim and M. R. Piano The Natriuretic Peptides: Physiology and Role in Left-Ventricular Dysfunction Biol Res Nurs, July 1, 2000; 2(1): 15 - 29. [Abstract] [PDF]
|
|
|
|
|
|
R. Levi, R. Maruyama, N. C. E. Smith, and N. Seyedi Is the lower mortality in patients treated with aspirin and angiotensin-converting enzyme inhibitors due to decreased norepinephrine release? J. Am. Coll. Cardiol., March 1, 2000; 35(3): 817 - 818. [Full Text] [PDF]
|
|
|
|
|
|
T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, N. Mabuchi, M. Hayashi, M. Ohnishi, M. Sawaki, M. Fujii, H. Horie, et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1 Eur. Heart J., December 2, 1999; 20(24): 1799 - 1807. [Abstract] [PDF]
|
|
|
|
 |
|
 P S Macdonald, A M Keogh, C Aboyoun, M Lund, R Amor, and D McCaffrey Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure Heart, November 1, 1999; 82(5): 589 - 593. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. D. Stolley, S. Saha, S. Hebbar, D. L. Dries, D. V. Exner, and M. J. Domanski Racial Differences in the Outcome of Left Ventricular Dysfunction N. Engl. J. Med., July 22, 1999; 341(4): 287 - 288. [Full Text]
|
|
|
|
 |
|
 R S McKelvie, C R Benedict, and S Yusuf Evidence based cardiology: Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction BMJ, May 22, 1999; 318(7195): 1400 - 1402. [Full Text]
|
|
|
|
|
|
D. V. Exner, D. L. Dries, M. A. Waclawiw, B. Shelton, and M. J. Domanski Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction J. Am. Coll. Cardiol., March 15, 1999; 33(4): 916 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Macdonald, A. M. Keogh, C. L. Aboyoun, M. Lund, R. Amor, and D. J. McCaffrey Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure J. Am. Coll. Cardiol., March 15, 1999; 33(4): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Dries, D. V. Exner, B. J. Gersh, H. A. Cooper, P. E. Carson, and M. J. Domanski Racial Differences in the Outcome of Left Ventricular Dysfunction N. Engl. J. Med., February 25, 1999; 340(8): 609 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Richards, M G Nicholls, T G Yandle, H Ikram, E A Espiner, J G Turner, R C Buttimore, J G Lainchbury, J M Elliott, C Frampton, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction Heart, February 1, 1999; 81(2): 114 - 120. [Abstract] [Full Text]
|
|
|
|
|
|
H P B.-L. Rocca, D Weilenmann, F Follath, M Schlumpf, H Rickli, C Schalcher, F E Maly, R Candinas, and W Kiowski Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings Heart, February 1, 1999; 81(2): 121 - 127. [Abstract] [Full Text]
|
|
|
|
|
|
O. Zolk, M. Flesch, G. Nickenig, P. Schnabel, and M. Bohm Alteration of intracellular Ca2+-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats Cardiovasc Res, July 1, 1998; 39(1): 242 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Richards, M. G. Nicholls, T. G. Yandle, C. Frampton, E. A. Espiner, J. G. Turner, R. C. Buttimore, J. G. Lainchbury, J. M. Elliott, H. Ikram, et al. Plasma N-Terminal Pro–Brain Natriuretic Peptide and Adrenomedullin : New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction Circulation, May 19, 1998; 97(19): 1921 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J E Sanderson, S K W Chan, C M Yu, L Y C Yeung, W M Chan, K Raymond, K W Chan, and K S Woo beta Blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol Heart, January 1, 1998; 79(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hatta, K. Yasuda, and R. Levi Activation of Histamine H3 Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia, J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 494 - 500. [Abstract] [Full Text]
|
|
|
|
 |
|
 D.-J. Choi, W. J. Koch, J. J. Hunter, and H. A. Rockman Mechanism of beta -Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased beta -Adrenergic Receptor Kinase J. Biol. Chem., July 4, 1997; 272(27): 17223 - 17229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Norepinephrine Predicts Cardiac Events in LV Dysfunction Journal Watch Cardiology, November 1, 1996; 1996(1101): 7 - 7. [Full Text]
|
|